AI Model Transparency

Understanding Our MRI Tumor Detection & Classification Systems

Three AI Models Available

Choose the right model for your analysis needs
Tumor boxes

Original Detection

RF-DETR v2 Architecture

Boxes around regions the model flags as possible tumors on DWI scans.

Output: Flagged regions, one tumor class

Boxes + tumor type

Tumor Classification (Object Detection)

YOLO26 Object Detection Architecture

Boxes plus a predicted type: glioma, meningioma or pituitary.

Output: Boxes and predicted type

Outlines + tumor type

Tumor Classification (Segmentation)

YOLO26 Instance Segmentation Architecture

Pixel outlines (masks) plus a predicted tumor type.

Output: Masks and predicted type

RF-DETR v2 Architecture

Real-time Detection Transformer for Medical Imaging

Model Details

  • RF-DETR v2
    Real-time Detection Transformer (Medium)
  • Detection
    Boxes for regions flagged as possible tumors (one class)
  • Speed
    Real-time inference capability

Capabilities

  • • Flags possible tumor regions
  • • Provides bounding box localization
  • • Outputs confidence scores
  • • Generates annotated images

Training Dataset

DWI images used during development

DWI MRI Scans

Diffusion-Weighted Imaging sequences for tumor detection

2,000+ Manual Annotations

Scans marked with labeled tumor regions

16,000+ Augmented Samples

Expanded through data augmentation techniques

Training Methodology

Data Processing & Model Optimization

Phase 1: Manual Annotation

2,000+ MRI scans annotated with tumor region markings

Phase 2: Preprocessing

Normalization, contrast enhancement, format standardization

Phase 3: Data Augmentation

Expanded to 16,000+ samples via rotation, scaling, brightness adjustments

Phase 4: Model Training

RF-DETR transformer architecture with hyperparameter optimization

Development Metrics

Measured on this model's validation split
97.9%
Validation mAP@50
Mean average precision at 50% overlap
97.6%
Validation precision
Share of predicted regions matching labels
97.0%
Validation recall
Share of labeled tumors found

Development metrics, measured on this model's held-out validation split of its own development dataset. Real-world performance on uploaded scans is substantially lower. Why real-world results are lower

YOLO26 Object Detection Architecture

Boxes and predicted tumor types

Model Details

  • YOLO26
    You Only Look Once v26 Architecture
  • Classification
    3 tumor types (Glioma, Meningioma, Pituitary)
  • Detection
    Bounding box localization

Capabilities

  • • Predicts one of three tumor types
  • • Provides bounding boxes for flagged regions
  • • Outputs per-class confidence scores
  • • Supports symptom consistency assessment

Training Dataset

Large-Scale Tumor Classification Data

9,711 MRI Scans

Original dataset with classified tumor types

3 Tumor Classes

Glioma, Meningioma, and Pituitary tumors

40,606 Augmented Samples

Expanded through data augmentation

Training Methodology

YOLO26 Object Detection Training Pipeline

Phase 1: Dataset Curation

9,711 MRI scans annotated with tumor type labels and bounding boxes

Phase 2: Preprocessing

Image normalization, resizing, and format standardization for YOLO input

Phase 3: Data Augmentation

Expanded from 9,711 to 40,606 samples using rotation, flipping, scaling, brightness, and mosaic augmentation

Phase 4: YOLO26 Training

Multi-class object detection training with optimized anchor boxes for tumor localization

Development Metrics

Measured on this model's validation split
81.6%
Validation mAP@50
Mean average precision at 50% overlap
82.1%
Validation precision
Share of predicted regions matching labels
76.6%
Validation recall
Share of labeled tumors found

Development metrics, measured on this model's held-out validation split of its own development dataset. Real-world performance on uploaded scans is substantially lower. Why real-world results are lower

YOLO26 Instance Segmentation Architecture

Pixel outlines and predicted tumor types

Model Details

  • YOLO26-Seg
    Instance Segmentation Architecture
  • Segmentation
    Pixel-level tumor boundary mapping
  • Classification
    3 predicted tumor types with pixel outlines

Capabilities

  • • Pixel outlines for flagged regions
  • • Instance-level segmentation masks
  • • Tumor type classification per instance
  • • Supports symptom consistency assessment

Training Dataset

Large-Scale Segmentation Training Data

9,711 MRI Scans

Original dataset with segmentation masks

Pixel-Level Annotations

Labeled tumor boundary masks for each class

40,606 Augmented Samples

Expanded through data augmentation

Training Methodology

YOLO26 Instance Segmentation Training Pipeline

Phase 1: Mask Annotation

9,711 MRI scans with pixel-level segmentation masks for each tumor type

Phase 2: Preprocessing

Image and mask normalization, resizing, and format standardization

Phase 3: Data Augmentation

Expanded from 9,711 to 40,606 samples with synchronized image-mask augmentation

Phase 4: YOLO26-Seg Training

Instance segmentation training with mask prediction head for region outlines

Development Metrics

Measured on this model's validation split
84.4%
Validation mAP@50
Mean average precision at 50% overlap
89.1%
Validation precision
Share of predicted regions matching labels
80.5%
Validation recall
Share of labeled tumors found

Development metrics, measured on this model's held-out validation split of its own development dataset. Real-world performance on uploaded scans is substantially lower. Why real-world results are lower

Development metrics vs. real-world scans

What the numbers measure, and what uploaded scans have taught us

How to read the development metrics

Each number above was measured on a held-out validation split of that model's own development dataset. mAP@50 is mean average precision at 50% overlap between predicted and labeled regions. Precision is the share of predicted regions that matched a labeled tumor. Recall is the share of labeled tumors the model found. These are not real-world accuracy measurements. The three models do different tasks on different datasets, so their numbers can't be compared with each other.

Why real-world results are much lower

  • Familiar images: The validation split comes from the same curated collection as the training data. It measures familiar-looking images, not scans from new hospitals.
  • Scanners: Scanner vendor, magnetic field strength and reconstruction settings change brightness, contrast, noise and resolution. The same anatomy can look different from one machine to another.
  • Sequences and protocols: Original Detection was trained on DWI, but uploads can be T1, T2, FLAIR or contrast-enhanced images, with different slice thickness, orientation and slice position.
  • The image path: Uploads may be screenshots, phone photos or crops with text overlays, different windowing and JPEG compression that the training images did not have.
  • Patients and case mix: Patients differ in age, may have post-surgical changes or conditions the models never saw. The classification models only know glioma, meningioma and pituitary tumors, so they must choose one even when none applies.
  • One slice vs. a full study: The models see one 2D slice. Radiologists read full 3D studies with several sequences, earlier scans and clinical history.
  • Confidence is not probability: Model confidence scores are not calibrated probabilities. A model can be confidently wrong on images unlike its training data.
  • Evaluation design: A general lesson in medical imaging research is that random image-level splits can put near-identical slices from the same patient in training and validation, making scores look better than they are. Patient-level splits and external test sets from other hospitals give more honest estimates; this is not a claim that such overlap happened here.

What we've learned from real uploads

Reviewing scans uploaded to this site, especially ones flagged with "Report Incorrect", shows that the models frequently fail on real-world scans: they can miss a tumor, flag normal tissue or predict the wrong tumor type. Strong development metrics did not transfer to real uploads. Data diversity and evaluation design matter as much as model architecture. This project is learning how to make models more adaptable across hospitals, scanners and patient populations. No real-world accuracy has been measured yet.

What we're working on (planned goals)

Today, only the "Report Incorrect" button and admin review of those reports exist. The following are goals, not features available today:

  • More diverse training data from multiple sites and MRI sequences.
  • Augmentation that simulates scanner differences and image-quality problems such as noise, blur, compression and contrast changes.
  • Consistent preprocessing and intensity normalization before images reach the model.
  • Patient-level data splits and testing on external data the models have never trained on.
  • Confidence calibration and detecting uploads unlike the training data.
  • Using reviewed "Report Incorrect" cases to find recurring failure patterns.

Symptom Consistency Assessment

Available for Classification Models (Object Detection & Segmentation)

YOLO26 classification models include an interactive symptom checklist that calculates a "Combined Consistency Score" weighing both AI confidence and reported symptoms.

Scoring Formula

Score = (55 × AI Confidence) + (Symptom Points)

  • • AI Confidence: 55% weight (0-55 points)
  • • Symptom Checklist: 45% weight (0-45 points)
  • • Guardrail: If AI confidence < 25%, symptom cap at 10 points

Tumor-Specific Symptoms

Glioma: Headaches, seizures, cognitive changes
Meningioma: Vision changes, hearing loss, weakness
Pituitary: Vision issues, hormonal symptoms, fatigue

Educational Tool Only: The symptom checklist and its illustrative weights are for this research demo, not clinically validated and not a medical diagnosis.

!

Important Medical Disclaimer

These are experimental models, not clinical tools. Reviewing real uploads shows they frequently fail, even though their development metrics are strong. Model output is not a diagnosis; only a qualified radiologist reviewing the full study can interpret a scan.

Technical Implementation

How the models integrate with our platform

API Integration

  • • Serverless Workflow endpoints
  • • Real-time processing via RESTful API
  • • Secure image transmission and results
  • • Multi-model support (RF-DETR, YOLO26 OD, YOLO26 Seg)

Output Processing

  • • Confidence score analysis
  • • Bounding box / segmentation mapping
  • • Annotated image generation
  • • PDF report with radiological descriptions

Questions About Our AI Models?

For technical inquiries about our model implementations or training methodology, contact our development team.

Contact Technical Team